Jacques Glowinski (30 August 1936 – 5 November 2020) was a French pharmacist and biology researcher specializing in neurobiology and neuropharmacology[1] for which he is considered one of the founding fathers in France.
[4] From 1963 to 1966, he was invited to continue his work at the National Institute of Health (Bethesda, United States) as part of Julius Axelrod's team (Nobel Prize in Medicine in 1972) in the prestigious Clinical Sciences Laboratory directed by S. Kety, pioneer with L. Sokolof in brain circulation studies.
During this internship, Jacques Glowinski also collaborated with L. Iversen and S. Snyder and published, among his hundreds of publications, about twenty articles on the brain metabolism of catecholamines and demonstrated in particular the mechanism of action of tricyclic antidepressants.
He created a small research group at the Collège de France in the Chair of Neurophysiology under Professor Alfred Fessard and quickly established a fruitful collaboration with the pharmaceutical industry.
[7][8] Neurotransmission, neuropeptides (including tachykinins), metabolic and functional properties of monoaminergic and cholinergic regulatory systems, neural circuits of the basal ganglia, relationships between the prefrontal cortex and the basal ganglia, development of dopaminergic systems, properties of astrocytes[9] and astrocyto-neuronal relationships, Parkinson's disease, schizophrenia, drug addiction, neurotoxicity, these were the main research areas of this laboratory, which has developed various research avenues.